USSTOCK.TODAY
Weekend. Closed Log in Sign up
ETF Profiles

PJP ETF Explained: Returns, Expense Ratio, Holdings and Alternative ETFs

Updated June 10, 2026 · First published June 10, 2026

The Invesco Pharmaceuticals ETF (PJP) is a passive thematic product that invests in large US pharmaceutical companies that develop and sell new drugs. Its pharma-heavy structure is sensitive to drug pricing regulation, and differences in composition and weighting versus XPH, IHE and PPH are the key selection criteria.

Briefs · earnings · signals, first Subscribe
🏷️

What Is the Invesco Pharmaceuticals ETF?

This is a passive thematic ETF that tracks an index of large US pharmaceutical companies that develop and sell new drugs. By concentrating on the pharmaceutical industry, it gives exposure to new drug development and the earnings of pharmaceutical companies.

It suits investors who want concentrated exposure to the pharmaceutical sector and are willing to accept new drug development outcomes, drug pricing regulation, and sector concentration volatility.

It is a passive (index tracking) ETF managed by Invesco.

💰

How Does the Invesco Pharmaceuticals ETF Invest?

ItemDetails
Investment TargetUS pharmaceutical companies
Management StylePassive (index tracking)
ThemePharmaceuticals
Dividend FrequencyQuarterly dividends
Expense Ratio0.58%

It tracks an index of large US pharmaceutical companies that develop and sell new drugs. Using a weighting method that considers both momentum and fundamentals, it diversifies across pharmaceutical companies. It reflects the trends in new drug development and the pharmaceutical industry, but with a composition that differs from market-cap weighting.

  • Focused on the US pharmaceutical industry
  • Weighting that considers momentum and fundamentals
📐

Invesco Pharmaceuticals ETF Size and Costs (AUM and Management Fee)

Assets under management (AUM) stand at $586.7M, and the Expense Ratio is 0.58% per year.

The main point of comparison is its narrower pharmaceutical-focused composition versus broad healthcare ETFs and biotech ETFs.

📈

Invesco Pharmaceuticals ETF Performance and Trends

1-Year Price Performance
Dividend & Yield
Dividend Yield 0.90%
Annual Dividend (TTM) $1.13
1Y Return +21.9%
Next Ex-Dividend Date 9/21/2026
52-Week Price Range
$125
Low $99 High $133
vs. low +25.96% vs. high -5.91%

Pharmaceutical stocks are driven by clinical trial results, drug pricing regulation, mergers and acquisitions, and the interest rate environment. They tend to be strong when new drug successes and M&A expectations stand out, and weak when concerns over drug pricing regulation grow. Because the ETF centers on large pharmaceutical companies, its volatility tends to be somewhat lower than that of biotech.

Fund flows into pharmaceutical stocks split depending on new drug momentum, drug pricing policy, and demand for defensive characteristics. When concerns about an economic slowdown grow, money can also flow in for their defensive nature. It is also worth noting that performance varies with clinical trial results and the regulatory environment.

⚔️

Invesco Pharmaceuticals ETF Pros and Cons

Its strengths are its pharmaceutical sector focus and defensive character, while drug pricing regulation, clinical trial risk, and sector concentration are points to consider.

💪 Key Strengths

Pharmaceutical Exposure
It gives concentrated exposure to large pharmaceutical companies that develop and sell new drugs.
Defensive Character
Demand for essential medicines can make it relatively resilient during economic slowdowns.
Diversified Composition
It spreads investment across multiple pharmaceutical companies, reducing single-stock risk.

⚠️ Points to Watch

Drug Pricing Regulation
Regulations that cut drug prices can hurt pharmaceutical companies' earnings and share prices.
Clinical Trial Risk
Failed clinical trials for new drugs or patent expirations can significantly affect share prices.
Sector Concentration
Because it is concentrated in a single pharmaceutical theme, the diversification benefit is limited.
🔄

Invesco Pharmaceuticals ETF Alternatives and Related Products

For equal-weighted exposure to pharmaceuticals, direct alternatives include XPH, and for other forms of pharmaceutical exposure, products such as IHE are also worth comparing. For a focus on global large-cap pharmaceuticals, products such as PPH can also be considered. This ETF's differentiators are its narrower exposure to the US pharmaceutical industry and a weighting that considers momentum and fundamentals.

Peer Comparison ETFs
TickerNamePriceChangeAUMTotal Expense RatioDividend Yield1Y
VFHVFHVanguard Financials ETF$131.80-1.9%$12.9B0.09%1.78%+6.0%
ONEQONEQFidelity Nasdaq Composite Index ETF$89.52-4.9%$9.9B0.21%0.57%+3.0%
VISVISVanguard Industrials ETF$299.47-3.2%$7.4B0.09%1.02%+5.7%
IYFIYFiShares U.S. Financials ETF$126.18-2.1%$3.7B0.37%1.54%+4.6%
FVFVFirst Trust Dorsey Wright Focus 5 ETF$66.65-2.2%$3.6B0.89%0.39%+13.9%
Top Holdings
TickerNameWeightPriceChangeMarket CapP/EDividend Yield
OABIOABIOmniAb Inc-$4.66-7.4%$679.7M--
ABTAbbott Laboratories0.06%$103.00-0.8%$178.4B38.02.53%
ABBVAbbvie Inc0.05%$286.20+0.9%$505.9B49.32.4%
AMGNAMGEN Inc0.05%$435.64-0.7%$235.6B25.32.31%
PFEPfizer Inc0.05%$27.40-0.5%$156.2B39.26.28%
JNJJohnson & Johnson0.05%$270.47+1.3%$651.1B41.01.97%
MRKMerck & Co Inc0.05%$133.72+0.7%$329.7B136.62.55%
✅

Invesco Pharmaceuticals ETF Investor Checkpoints

Here are the points to review before investing in PJP. Its pharmaceutical sector focus and defensive character are appealing, but drug pricing regulation, clinical trial risk, and sector concentration should be checked in advance. It is also advisable to compare it with broad healthcare and biotech products.

CheckpointWhat to CheckCurrent Status
💊 Pharmaceutical ExposureReview the composition of large pharmaceutical companiesPharma-focused
⚖️ Drug Pricing RegulationReview drug price cut policiesNeeds checking
⚗️ Clinical Trials and PatentsReview new drug trials and patent expirationsNeeds checking
🏥 Defensive CharacterReview demand for essential medicinesRelatively resilient

Drug price cut regulations, failed clinical trials for new drugs, and patent expirations are the main variables for short-term performance, and because the ETF is concentrated in a single pharmaceutical theme, it is sensitive to regulatory and clinical news. Given its sector concentration, it can also fall along with the market during periods of weakness.

It is a suitable candidate for investors who want concentrated exposure to the pharmaceutical sector. If you want equal-weighted pharmaceuticals or a different form of pharmaceutical exposure, compare products such as XPH and IHE, and if you want a pharmaceutical focus, compare this product alongside them before choosing.

Briefs · earnings · signals, first Subscribe

Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.

This article reflects information as of June 10, 2026.

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →